Related Experiment Videos
[D-penicillamine does not affect the liver and kidney function in newborn infants nor the in vitro function of
1Hajdú-Bihar Megyei Onkormányzat Dr. Kenézy Gyula Kórház-Rendelöintézet, Debrecen, Csecsemö- és Gyermekosztály.
Insights
D-penicillamine (DPA) showed no adverse effects on neonatal liver or kidney function in short-term use. The drug did not impact neutrophil phagocytic or killing activities in vitro.
Area of Science:
- Neonatal medicine
- Pharmacology
- Immunology
Context:
- D-penicillamine (DPA) has historical uses in treating neonatal hyperbilirubinemia and preventing retinopathy of prematurity.
- Investigating the safety and immunological effects of DPA in neonates is crucial.
Purpose:
- To assess the impact of short-term D-penicillamine (DPA) administration on renal and liver function in neonates.
- To evaluate the in vitro effects of DPA on human neutrophil functions, including superoxide anion generation, beta-glucuronidase release, phagocytosis, and intracellular killing.
Summary:
- Short-term D-penicillamine (DPA) treatment (3-4 days) in neonates did not result in pathological changes in renal or liver function.
- In vitro studies demonstrated that DPA, at examined concentrations, did not affect the phagocytic capacity or intracellular killing activity of human neutrophils.
Impact:
- This study suggests D-penicillamine (DPA) is safe for short-term use in neonates regarding major organ functions.
- Findings indicate DPA does not interfere with essential neutrophil immune responses, supporting its use in specific neonatal conditions.
Abstract:
D-penicillamine was introduced to treat neonatal hyperbilirubinaemia in 1973 and to prevent retinopathy of prematurity in 1980. In this study we investigated the renal and liver functions of neonates treated with DPA and the in vitro effect of the drug on superoxide anion generation and beta-glucuronidase release as well as on phagocytic and intracellular killing activation on human peripheral blood granulocytes. Our data concerning the renal and liver functions before and after 3 to 4 days DPA treatment reveal no pathological change during short-term administration in the neonatal period. Furthermore, none of the examined DPA concentrations influenced the phagocytic or killing activity of neutrophils.